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Abstract
Background: The mechanisms involved in lung cancer (LC) progression are poorly understood making discovery
of successful therapies difficult. Adaptor proteins play a crucial role in cancer as they link cell surface receptors to
specific intracellular pathways. Intersectin-1s (ITSN-1s) is an important multidomain adaptor protein implicated in
the pathophysiology of numerous pulmonary diseases. To date, the role of ITSN-1s in LC has not been studied.
Methods: Human LC cells, human LC tissue and A549 LC cells stable transfected with myc-ITSN-1s construct
(A549 + ITSN-1s) were used in correlation with biochemical, molecular biology and morphological studies. In
addition scratch assay with time lapse microscopy and in vivo xenograft tumor and mouse metastasis assays
were performed.
Results: ITSN-1s, a prevalent protein of lung tissue, is significantly downregulated in human LC cells and LC
tissue. Restoring ITSN-1s protein level decreases LC cell proliferation and clonogenic potential. In vivo studies
indicate that immunodeficient mice injected with A549 + ITSN-1s cells develop less and smaller metastatic tumors
compared to mice injected with A549 cells. Our studies also show that restoring ITSN-1s protein level increases
the interaction between Cbl E3 ubiquitin ligase and Eps8 resulting in enhanced ubiquitination of the Eps8
oncoprotein. Subsequently, downstream unproductive assembly of the Eps8-mSos1 complex leads to impaired
activation of the small GTPase Rac1. Impaired Rac1 activation mediated by ITSN-1s reorganizes the cytoskeleton
(increased thick actin bundles and focal adhesion (FA) complexes as well as collapse of the vimentin filament
network) in favor of decreased LC cell migration and metastasis.
Conclusion: ITSN-1s induced Eps8 ubiquitination and impaired Eps8-mSos1 complex formation, leading to
impaired activation of Rac1, is a novel signaling mechanism crucial for abolishing the progression and metastatic
potential of LC cells.
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Background
Metastasis is the primary cause of death in most human
cancers, including LC [1]. Metastasis is a multistep
process in which cells from the primary tumor migrate
through the extracellular matrix (ECM), enter the circu-
lation through tumor angiogenesis and disseminate to
distant sites where proliferation begins again [2, 3]. The
signal transduction initiated by receptor tyrosine kinases
(RTK) plays a pivotal role in the regulation of prolifera-
tion and migration of cancer [4]. In most signaling path-
ways the adaptor proteins link cell surface receptors,
including RTK, to specific intracellular pathways regulat-
ing the activation status of kinases and controlling the
cross-talk between signaling cascades [5]. ITSN-1s is
one such protein that plays a crucial role in intracellular
signal transduction, linking activated receptors to down-
stream targets by binding to specific phospho-tyrosine-
containing sequences and proline-rich motifs [6–8].
Studies have shown that ITSN-1s is critical for endo-
cytosis of cell surface receptors [9]. Endocytic deficiency
induced by ITSN-1s knockdown alters the Smad2/3-
Erk1/2 signaling balance downstream of transforming
growth factor receptor type I leading to proliferation
and neo-vascularization of lung endothelial cells [9].
Due to its multimodular structure, ITSN-1s is involved
in multiple protein-protein interactions with a pivotal
role in cell growth, apoptosis, cell cycle regulation, DNA
damage repair and innate immune response [10, 11].
There are two ITSN genes in humans (ITSN-1 and
ITSN-2), each encoding a short (ITSN-s) and long
(ITSN-l) isoform due to mRNA alternative splicing of
each gene [12]. ITSN-s contains two N-terminal Eps15
homology domains (EH1 and EH2), a coiled-coil (CC)
region, and five Src homology 3 domains (SH3A-E). The
EH domains promote interaction with Asp-Pro-Phe se-
quences that are present in numerous endocytic adaptor
proteins and the SH3 domains recognize proline-rich
domains present in a variety of cytoskeletal and signaling
proteins [13]. ITSN-l in addition has an extended C-
terminus which comprises the Dbl and pleckstrin (DH-
PH) domains with guanine nucleotide exchange factor
(GEF) activity for Rho GTPases, especially Cdc42 [14].
ITSN-1l is specific to the brain and is absent in lung tis-
sue whereas ITSN-1s and ITSN-2s and ITSN-2l are
expressed ubiquitously [15]. ITSN-1s especially is highly
prevalent in lung tissue and plays a significant role in
the pathogenesis of pulmonary diseases such as pulmon-
ary hypertension and acute lung injury [9, 16, 17]. ITSN-
1s interacts with the Cbl E3 ubiquitin ligase with an
essential role in tumorigenesis and metastasis [7, 8, 18].
E3 ubiquitin ligases are often deregulated in human can-
cers, including LC, and their deregulation has been
shown to contribute to cancer development [19]. In
addition, ITSN-1s via its SH3 domains interact with
mSos1 which is a GEF for the GTPase proteins Ras and
Rac1 and is also an Eps8-interacting protein [20]. Eps8
interacts with the actin cytoskeleton to facilitate Rac1
localization and subsequent cell migration [21]. In
addition, ITSN-1s binds to CdGAP (GTPase-activating
protein) via its SH3 domains with activity towards
Cdc42 and Rac1 [22, 23].
Clinical evidence suggests that ITSN-1s may also be
important in cancer. The ITSN-1 gene is present on
chromosome 21 in the Down syndrome critical region
[12]. As a result, ITSN-1 mRNA and protein levels are
elevated in these patients [24]. In a cohort prospective
registry study these patients had a significantly lower in-
cidence of LC compared to the age matched general
population [25].
Based on this background, we hypothesized that
ITSN-1s may play a role in LC progression. Our novel
findings demonstrate that ITSN-1s is significantly down-
regulated in human LC cells and LC tissue. Restoring
ITSN-1s protein level increases ubiquitination of Eps8
oncoprotein and impairs Eps8-mSos1 interaction, lead-
ing to decreased activation of Rac1 GTPase resulting in
cytoskeleton rearrangements capable of abolishing the
progression and metastatic potential of LC cells.
Methods
Cell culture and transfection
A549 cells were grown in HAM’s F12 medium, contain-
ing 10 % FBS, 1 % 1-Alanyl-L-glutamine, and 1 % anti-
mycotic, at 37 °C in a 5 % CO2 incubator. Bronchial
cells were grown in airway epithelial basal cell medium
(0.25 % HLL, 3 % L-glutamine, 0.4 % Extract P, 1 % air-
way epithelial cell supplement). Subconfluent A549 cells
were transfected with a myc-tagged full-length ITSN-1s
DNA cloned into the mammalian vector pcDNA3.1Myc/
His (GeneCopoeia™, Rockville, MD), using 7:2 ratio of
Fugene HD transfection reagent (μl) to DNA (μg) [26].
For stable transfection, ITSN-1s transiently transfected
cells were grown in 100 cm2 dishes with 1 mg/ml G418.
HAM-F’12 medium containing 1 mg/ml G418 was
replenished every other day for about 2 weeks until
stable transfected A549 cells began to grow. At that
point the concentration of G418 in HAM’s F12 medium
was switched to 800 μg/ml for a week and then main-
tained at 500 μg/ml. For siRNA transfection, a set of 4
siRNA targeting Cbl gene, control siRNA and Transfec-
tion Reagent from Dharmacon (Lafayette, Co) were
used; 0.1×106 cells in 2 ml complete medium without
antibiotics were seeded in 6-well plates and grown to
70 % confluence prior to transfection. Control siRNA
and Cbl siRNA (5 μM) were diluted in transfection
medium (4 μl) as per manufacturer’s instructions and
added dropwise over the cells. Transfected cells were in-
cubated at 37 °C in a 5 % CO2 for 8 h without changing
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medium. Then the medium was replaced with normal
growth medium. Optimal siRNA/transfection reagent ra-
tio and transfection time were determined in pilot
studies.
Specific Antibodies (Ab) were as follows: ITSN-1, Eps8
(BD Biosciences, San Jose, CA); mSos1, Rac1, Cbl, control
IgG, Ub, vinculin, vimentin (Santa Cruz Biotechnology,
Santa Cruz, CA); ITSN-1, Actin (Sigma-Aldrich, St. Louis,
MO). All fluorophor-conjugated Abs and the Prolong
Antifade reagent were from Molecular Probes (Eugene, OR).
Human LC specimens
LC tissue micro array (TMA) with 20 cases of lung
adenocarcinoma and 20 cases of normal lung tissue
was obtained from US Biomax (Rockville, MD). LC
cell lysates, frozen lung tissue specimens and normal
lung controls were provided by Dr. Jeffrey Borgia,
Rush University Medical Center (Chicago, IL). Pri-
mary lung adenocarcinoma samples (n = 10) in
paraffin-embedded blocks were obtained from the De-
partment of Pathology, Rush University Medical Cen-
ter (Chicago, IL). The studies were approved by the
Rush Human Subject Committee. Informed consent
from the patients was obtained in all cases. Lung
histological sections were analyzed in each case to confirm
the diagnosis. The LC cell lines were derived from lung
tissue as follows: A549, lung carcinoma; H358, bronch-
ioalveolar carcinoma; H1703, squamous cell carcinoma;
H1437, adenocarcinoma (stage 1; pleural effusion); H2009,
adenocarcinoma (stage 4; lymph node).
Quantitative PCR
Lung tissues and cells were lysed using the Qiagen QIA
Shredder homogenizer; total RNA was isolated using the
RNeasy Mini RNA isolation kit (Qiagen, Valencia, CA).
The cDNA was synthesized from 2 μg RNA using High-
Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Carlsbad, CA). RT-PCR was performed on
an Applied Biosystems 7900HT machine [17]. The rela-
tive mRNA levels were normalized to housekeeping gene
cyclophillin, and determined by calculating the ΔΔCt
value as per manufacturer’s guidelines.
Soft agar assay
Anchorage-independent growth was determined by
assaying colony formation in soft agar [28]. Briefly, 1 ×
105 A549 and A549 + ITSN-1s cells resuspended in 5 ml
HAM’s F12 medium (containing 10 % FBS and 0.28 %
Difco Nobal Agar) were plated in triplicates onto 35 mm
dishes over a 2.5 ml layer of solidified HAM’s F12/10 %
FBS and 0.58 % agarose. The cells were incubated in hu-
midified 5 % CO2, 95 % air, at 37 °C and fed by adding
2 ml of HAM’s F12/10 % FBS every 2–3 days. Thirty
days after seeding, colonies were stained with 0.01 %
crystal violet dye and counted. Pictures were taken by
Alpha Imager HP digital scanner.
MTT assay
A549 cells and A549 + ITSN-1s cells were subjected to
MTT cell proliferation [17]. Briefly, triplicate aliquots of
cells (106 cells suspended in 100 μl complete medium)
were serially diluted in medium, onto a 96-well plate.
After 48 h, 10 μl MTT Reagent were added to each well.
After 5 h incubation, 100 μl of detergent was added, the
plate was covered and kept in the dark at room
temperature (RT) overnight. The next day the absorb-
ance at 570 nm was determined using a Dynex micro-
plate reader. Parallel triplicate experiments using non-
treated cells were performed; cells were counted using a
hemocytometer and a growth curve was generated to re-
late the OD570 values to the cell number per well.
Immunoprecipitation and western blot
Cells were lysed in a buffer containing 50 mM Tris-HCl-
pH8.0, 150 mM NaCl, 1 % NP-40, 1 mM Na3VO4, 1 mM
PMSF, and protease and phosphatase inhibitors for 2 h at
4 °C. Lysates were centrifuged (45 min, at 45000 rpm, at
4 °C) and stored at −20 °C. Protein content was determined
using Micro Bicinchoninic acid assay. For immunoprecipi-
tation (IP), cell lysates (500 μg of total protein) were pre-
cleared using 25 μl protein A/G slurry for 30 min at RT.
The supernatants were then incubated with 3 μg mSos1,
Cbl or isotype matched IgG Abs for 1 h at RT. 40 μl of pro-
tein A/G slurry (Santa Cruz Biotechnology, Santa Cruz,
CA) were then added to the supernatants and incubated
at 4 °C overnight. The bound proteins were resolved on
5–20 % SDS-PAGE. Western blot (WB) was performed
using primary Abs and appropriate secondary Abs [26].
TrueBlot® ULTRA secondary Ab (Rockland Immunochemi-
cals, Limerick, PA) was used for Rac1 to avoid background
from the light chain band. For detection of Eps8 ubiquitina-
tion by WB, 5 mM N-ethylmaleimide was added in the IP
buffer to prevent the cleavage of polyubiquitin chains [9].
Analysis of soluble to insoluble vimentin ratio
A549 cells and A549 + ITSN-1s cells were grown under
similar conditions, trypsinized and counted. Equal num-
ber of cells were lysed and centrifuged for 5 min at
10,000xg. The pellet (vimentin full length filaments) and
60 μg total protein of supernatant (collapsed vimentin
filaments) were solubilized in equal volume of Laemmli
sample buffer, denatured by boiling, and equal volumes
were resolved on 5–20 % SDS-PAGE and analyzed by
WB with vimentin Ab [29].
Immunofluorescence and immunohistochemistry
Immunofluorescent and phalloidin staining of cells
grown on coverslips was performed [30]. Briefly, cells
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were seeded on non-collagen coated coverslips in 6-well
plates. Cells were washed three times with cold PBS,
followed by fixation and permeabilization with methanol
at −20 °C for 5 min. Methanol was immediately removed
and blocking buffer (PBS with 1 % BSA) was added for
45 min at RT. Following removal of blocking buffer, cells
were incubated with primary Ab (ITSN-1 Ab (1:250),
vinculin Ab (1:250) or vimentin Ab (1:250) in 0.1 %
BSA/PBS) for 1 h at RT. The cells were washed with
0.1 % BSA in PBS three times for 10 min each. Cover-
slips were then incubated with appropriate secondary
Ab (at dilution 1:500 in 0.1 % BSA/PBS) for 1 h, pro-
tected from light, at RT followed by washing as above.
For phalloidin Alexa Flour (AF) 488 staining, cells were
fixed in 3.7 % paraformaldehyde in PBS for 15 min at
RT, permeabilized in 0.1 % Triton X-100 for 5 min on
ice, and stained with phalloidin AF488 for 30 min at RT.
Cells were mounted with Prolong Antifade reagent. For
morphometry, the number of vinculin clusters per
250 μm2 was counted in 3 randomly chosen areas along
the cell perimeter and was averaged from different ex-
periments performed in triplicates. At least 50 cells were
counted per experiment. Micrographs were taken with a
Zeiss AxioImager M1 microscope equipped with a
digital camera. All images used for quantification were
acquired using identical parameters per experiment.
Immunohistochemistry (IHC) on paraffin-embedded
LC specimens and TMA using the ITSN-1 Ab was per-
formed as previously described by us [17]. ITSN-1s Ab
from Sigma-Aldrich (St. Louis, MO) was used for im-
munofluorescence and IHC.
Actin polymerization assay
Briefly, cells were washed in PBS and collected into
1.5 ml Eppendorf tubes. Cell pellets were then resus-
pended in 100 μl of lysis buffer I (20 mM Hepes-NaOH,
pH 7.2, 100 mM NaCl, 1 mM sodium orthovanadate,
50 mM NaF, 1 % Triton X-100, protease inhibitors) for
1 h and centrifuged for 20 min at 22,000 rpm [30].
Supernatants were saved as G-actin fractions; the pellet
was resuspended in lysis buffer II (15 mM Hepes-
NaOH, pH 7.5, 0.15 mM NaCl, 1 % Triton X-100, 1 %
sodium deoxycholate, 0.1 % SDS, 10 mM EDTA, 1 mM
dithiothreitol, 1 mM sodium orthovanadate, protease
inhibitors) for 1 h and then centrifuged at 45,000 rpm
for 40 min. The ensuing supernatants represented the F-
actin fractions. Equal protein amounts were loaded onto
4–12 % SDS-PAGE. Actin was detected by immunoblot-
ting with actin Ab and quantified by densitometry.
Scratch assay
Cells were seeded into 12-well plates and grown to 90–
100 % confluence. A sterilized micro-pipette tip was
used to generate a scratch across the cell layer. Cells at
multiple points along the scratch were imaged every
15 min over a 48 h period using time-lapse microscopy
using a Zeiss AxioVert Z1 microscope. Images were cap-
tured at 100× magnification. Cell migration measure-
ments were made using NIH imageJ software.
Mouse metastasis and xenograft tumor assays
Protocols were approved by the Institutional Animal
Care and Use Committee and Institutional Biosafety
Committee of Rush University. Five week old immuno-
deficient male mice (Jackson Labs, ME) were used. For
metastasis assay, mice were injected retro-orbitally with
2 × 106 cells in 0.1 ml PBS. After 12 weeks mice were
sacrificed. The lungs were removed, fixed in 4 % formal-
dehyde/PBS, paraffin-embedded, dissected and stained
with hematoxylin and eosin (H&E) (27). For the xeno-
graft tumor assay, 107 cells resuspended in PBS were
mixed with matrigel (BD Bioscience, Bedford, MA) at a
1:1 volume ratio in 200 μl of medium without serum
and injected subcutaneously into the flanks of mice [31].
After 4 weeks, mice were sacrificed and the tumor was
resected. Pictures were taken and the tumor area was
measured NIH imageJ software.
Cdc42/Rac1/RhoA activation assay
Cell lysates prepared in ice-cold lysis buffer were centri-
fuged (10,000 g, 4 °C for 1 min) to remove cell debris and
then incubated with 40 μl of p21 activated kinase (PAK)-
GST beads [Cdc42/Rac1 activation kit (Cytoskeleton,
Denver, CO)] or 50 ml of Rhotekin-GST beads for RhoA
for 60 min at 4 °C, as per manufacturer’s instructions.
Beads were washed and boiled for 2 min in 20 μl of
Laemmli sample buffer; samples were run in parallel with
total cell lysates and GTP/GDP control, and WB per-
formed with Cdc42/Rac1/RhoA Ab. Activation of Cdc42/
Rac1/RhoA in control and transfected cells was deter-
mined by densitometry.
Statistical analysis
All findings were confirmed in three to five different ex-
periments performed under identical conditions. Images
were acquired using identical parameters. Densitometry
analysis was performed using NIH ImageJ software. Data
are expressed as mean or median ± SE. Comparisons
were made using unpaired student’s t-test. P values less
than 0.05 were considered statistically significant.
Results
ITSN-1s protein and mRNA levels are downregulated in
LC cells and tissues
To address whether ITSN plays a role in LC, we exam-
ined ITSN-1s protein level in human LC cells by WB
with ITSN-1 Ab compared to human bronchial cells
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(Fig. 1a). Downregulation of ITSN-1s protein level was
consistent for all LC cell lines (Fig. 1a, lanes b – f vs. a).
Densitometry indicated that the extent of downregulation
ranged from 42 % to undetectable levels in H1437 adeno-
carcinoma cells (Fig. 1a, e). To determine if downregula-
tion of ITSN-1s is due to inhibition of transcription or
post-translational modifications, qPCR analyses were per-
formed. ITSN-1s mRNA levels were assessed in A549 cells
compared to bronchial cells, and in adenocarcinoma tis-
sue (Table 1), compared to non-LC tissue (Fig. 1b). Similar
to protein level, ITSN-1s mRNA level was decreased in
LC by 38 to 81 %.
Fig. 1 ITSN-1s protein and mRNA levels are decreased in LC patients. aWB using ITSN-1 Ab of cell and lung tissue lysates resolved by SDS PAGE (70 μg total
protein/lane). Human LC cells (b - f) were compared to control bronchial cells (a). The cell lines were as follows: b- A549, c- H358, d- H1703, e- H1437, f-
H2009; MW – molecular weight. Data are shown as ITSN-1s/actin ratio. The bands between MW 100–150 were included in densitometry analysis. b qPCR
analyses of ITSN-1s mRNA levels in A549 cells (b) and lung adenocarcinoma cases (c–f) compared to controls (bronchial cells and normal tissue) (a). Data are
shown as percentage decrease by comparison to controls. Error bar represents mean ± SE; *p< 0.05. The above data are representative of 3 independent
experiments performed under identical experimental conditions. c Representative ITSN-1s IHC staining of paraffin-embedded adjacent normal lung tissues
(a, a1) and lung adenocarcinoma tissue (b, b1). d Representative ITSN-1s IHC staining of TMA specimens from normal lung (a) and lung adenocarcinoma (b).
e The percentage of patients with high and low ITSN-1s protein level were calculated in 3 groups: normal, well-differentiated and moderately or poorly
differentiated. Images were acquired using identical parameters. Bars: 20 μm (a, b); 5 μm (a1, b1)
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To further confirm this finding we examined the level
of ITSN-1s in 10 lung adenocarcinoma tissue samples
along with adjacent normal tissue. IHC analyses revealed
high ITSN-1s immunostaining in the normal bronchial
epithelial cells and adjacent normal alveoli (Fig. 1c, a,
a1) but much weaker or even undetectable levels in
some tumors (Fig. 1c, b, b1). The level of ITSN-1s was
reduced by more than 50 % compared to normal areas
in 8 of the adenocarcinoma samples examined. In
addition, we evaluated a TMA slide comprising 20 lung
adenocarcinoma samples: 10 grade 1 (well differentiated)
and 10 grades 2 or 3 (moderate to poorly differentiated)
and 20 normal tissue samples. Each TMA spot was ex-
amined and graded as having high (Fig. 1d, a) or low
ITSN-1s (Fig. 1d, b) protein level. The presence of at
least 25 % of cancer cells staining positive (intensity of a
minimum of 2 on a scale of 1 to 3 [32, 33]) within a pa-
tient sample was considered high ITSN-1s protein level.
A high ITSN-1s protein level was noted in 85 % of nor-
mal tissue, 30 % of grade 1 LC tissue and none of the
grades 2 or 3 LC tissue (Fig. 1e). Altogether these find-
ings provide strong evidence that ITSN-1s protein level
is downregulated in LC.
Next, we examined the subcellular distribution of ITSN-
1s in A549 cells compared to bronchial cells. Immuno-
fluorescent staining using ITSN-1 AF 488-conjugated
reporter Abs showed a wide subcellular distribution of
ITSN-1s in bronchial cells; the strong punctate pattern at
the plasma membrane and in the cytoplasm as well as in
the perinuclear area is consistent with ITSN-1s’ associ-
ation with the endocytic and Golgi vesicles (Fig. 2a, b, b1),
as previously reported in other cell types [26, 34]. A549
cells revealed a similar subcellular distribution of
ITSN-1s (Fig. 2a, a, a1), but a decreased staining in-
tensity, consistent with downregulation of ITSN-1s
protein level in LC.
To determine the impact of ITSN-1s downregulation
on LC, we first restored ITSN-1s protein level in A549
cells using myc-ITSN-1s. To improve and to preserve
the level of ITSN-1s long term, we created stable trans-
fected myc-ITSN-1s A549 cells (A549 + ITSN-1s;
Fig. 2b). Western blot using myc Ab (Fig. 2b, a) and
ITSN-1s Ab (Fig. 2b, b) demonstrated successful trans-
fection. Densitometry indicated restoration of ITSN-1s
protein level to 91 % of normal bronchial cells (Fig. 2c).
Immunoflorescence staining (ITSN-1s/AF 488 Ab) of
A549 + ITSN-1s cells (Fig. 2d, d, d1) compared to A549
cells (Fig. 2a, a, a1), demonstrated a similar subcellular
distribution but increased staining intensity, consistent
with restoration of ITSN-1s protein level.
ITSN-1s impairs LC cell proliferation, anchorage-
independent growth and tumor growth
Prior studies have shown that ITSN-1s regulates cell
proliferation via interaction with Ras [35]. Therefore, we
decided to investigate the effects of restoring ITSN-1s
protein level on LC cell proliferation. Briefly, A549 and
A549 + ITSN-1s cells were seeded in 100 cm2 plates in
triplicate, cultured for five days and counted. A549 +
ITSN-1s cells showed 30 % inhibition of cell prolifera-
tion compared to A549 cells (Fig. 3a). A549 and A549 +
ITSN-1s cells proliferation was also evaluated by the
MTT assay. A growth curve was generated to relate the
OD570 values to the cell number per well. The OD570
values for A549 + ITSN-1s cells were significantly lower
compared to A549 cells in all wells of the cell culture
plate (Fig. 3b). Three points on the linear part of the
proliferation curve were used for quantification of the
extent of cell growth inhibition. The results indicated a
20 % inhibition in proliferation of A549 + ITSN-1s cells
compared to A549 cells (Fig. 3c).
Since restoring ITSN-1s level impairs A549 cell prolifera-
tion, we examined whether ITSN-1s regulates anchorage-
independent growth, one of the hallmarks of cell trans-
formation [28]. We performed the soft-agar assay, a
validated in vitro assay for detecting malignant transform-
ation [28]. Cells started to form noticeable colonies after
30 days of culture. Although both A549 and A549 + ITSN-
1s cells formed colonies, the ability of A549 + ITSN-1s cells
to grow independent of anchorage was impaired compared
to A549 cells (Fig. 3d); the number of colonies was 80 %
lower (Fig. 3e), suggesting that ITSN-1s deficiency is an
important component in the anchorage-independent
growth of human LC cells.
To gain insight into ITSN-1s’ role in anchorage-
independent growth of LC cells in vivo, we performed a
xenograft tumor assay [31]. Immunodeficient mice were
injected subcutaneously with A549 and A549 + ITSN-1s
cells. Tumor development and growth were monitored
for 4 weeks at which point tumors were resected, photo-
graphed (Fig. 3f ), and measured. The tumors of mice
injected with A549 + ITSN-1s cells were 42 % smaller
than the tumors of mice injected with A549 cells
(Fig. 3g). Together these studies demonstrate that ITSN-
1s restoration in A549 cells significantly imapirs tumor
proliferation and anchorage-independent growth.
Table 1 Characteristics of the LC patients
Case Location Differentiation T N M Stage Sex Age
c LLL Poorly 2 2 0 3a F 64
d RLL Moderately 2 2 0 3a M 69
e RUL Well 1 0 0 1a F 67
f LLL Well 2 0 0 1b M 67
All cases were lung adenocarcinoma. The cases consisted of poorly to well-
differentiated samples from patients with early to advanced LC (stage 1 to 3).
LLL – left lower lobe, RUL – right upper lobe, RLL – right lower lobe; T – tumor
size, N – lymph node, M – metastasis, F - female, M – male, stage of LC is
based on TNM staging system [27]
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ITSN-1s impairs LC cell migration and metastasis
To address whether ITSN-1s deficiency interferes with
migration of LC cells, we performed a scratch assay
which preserves cell-cell interactions and is able to
mimic migration of cells in vivo [36], in conjunction
with time-lapse microscopy (Fig. 4a). A549 + ITSN-1s
cells showed statistically significant inhibition in scratch
closure as early as 3 h. The scratch was completely
closed by A549 cells at 24 h, whereas, A549 + ITSN-1s
cells closed only 60 % of the scratch (Fig. 4b) at this
same time point. The scratch closure is due to both cell
proliferation and cell migration into the scratch from
the periphery. The impact of either proliferation or mi-
gration in scratch closure cannot be determined just
based on the images, especially given that the cells are
grown to confluence prior to creating the scratch and
given that cancer cells migrate collectively in sheets/
lumps. To determine the impact of increased ITSN-1s
protein level on cell migration independent of cell prolif-
eration, cells grown to confluence were pretreated with
7.5 μg/ml of mitomycin C (Sigma-Aldrich, St. Louis,
MO) for 1 h which impaired further cell proliferation
efficiently without killing the cells (S1, A). Mitomycin C
is a widely used antibiotic because of its mild toxicity
and potent antitumor activity. Mitomycin C reacts cova-
lently with DNA, forming crosslinks between the com-
plementary strands of DNA. This prevents separation of
the complementary strands and thus inhibits DNA repli-
cation [37]. Based on the efficiency of inhibition noted
with mitomycin C, we believe the additional cells noted
in the scratch at 24 h in mitomycin C treated cells
(Additional file 1: Figure S1B, 2 panels on the right) is
due to predominantly cell migration of remaining cells
from the periphery. Mitomycin C treated A549 + ITSN-
1s cells compared to A549 controls significantly delayed
the scratch closure (S1, B) and overall impaired cell mi-
gration by 52 % (Fig. 4c). This finding demonstrates that
ITSN-1s plays a significant inhibitory role in cell migra-
tion in addition to its antiproliferative effects.
To further validate this finding we used a mouse me-
tastasis assay. A549 and A549 + ITSN-1s cells were
injected into the retro-orbital sinus of immunodeficient
mice [16]. After 12 weeks, mice were sacrificed and the
lungs were prepared for routine morphological analyses
[16]. For evaluation of pulmonary metastasis, lungs were
cut in 5 μm sections and stained with H&E. Five
sections throughout the whole lung per mice were
screened histologically, and the number of metastases
Fig. 2 Subcellular distribution of ITSN-1s in LC cells. a Immunofluorescent staining with ITSN-1 Ab followed by AF488 Ab in A549 cells (a, a1)
compared to bronchial cells (b, b1). b ITSN-1s protein expression was restored by stable transfection in A549 cells: myc-ITSN-1s protein level is
detected via myc Ab in transfected A549 cells (a); lysates of bronchial cells, A549 cells and myc-ITSN-1s transfected A549 cells (A549 + ITSN-1s)
were assessed for ITSN-1s protein level by WB using ITSN-1s Ab; actin used as loading control (b). c ITSN-1s protein level was quantified by
densitometry. d Immunofluorescent staining of A549 + ITSN-1s cells with ITSN-1 Ab shows a similar subcellular distribution but increased intensity in
A549 + ITSN-1s cells compared to A549 cells (d, d1). Error bar represents mean ± SE; *p < 0.05. Data are representative of 3 independent experiments
performed under identical experimental conditions. Images were acquired using identical parameters. Bars: 20 μm (a, b, d); 5 μm (a1, b1, d1)
Jeganathan et al. Molecular Cancer  (2016) 15:59 Page 7 of 17
was counted and classified based on their size as small
(diameter <200 μm), medium (diameter 200–500 μm) or
large (diameter >500 μm). A549 and A549 + ITSN-1s
injected mice developed tumors in the lung parenchyma
(Fig. 4d, d1, d5), pulmonary artery (Fig. 4d, d2, d6), sub-
pleura (Fig. 4d, d3, d7) and peribronchial lung (Fig. 4d,
d4, d8). Mice injected with A549 cells had significantly
more tumors per lung section (median 12.5 ± 0.7 vs. 2 ±
0.47, Fig. 4e), as well as more tumors per each size group
(median, small 6 ± 0.56 vs. 1 ± 0.12, medium 5 ± 0.47 vs.
1 ± 0.38, large 1 ± 0.39 vs. 0, Fig. 4f ) compared to mice
injected with A549 + ITSN-1s cells. Together these find-
ings are consistent with an important role of ITSN-1s in
restricting LC proliferation, migration and metastasis.
To determine if ITSN-1s was still present in the
emergent tumors, we performed immunofluorescence
staining of lung sections with ITSN-1s antibody.
Tumors of all size in mice injected with A549 cells
showed very low to undetectable levels of staining for
ITSN-1s (Additional file 2: Figure S2, A, C). However,
mice injected with A549 + ITSN-1s cells showed vari-
ability in ITSN-1s expression based on the size of the
tumors. Smaller tumors showed higher ITSN-1s stain-
ing throughout the tumor (Additional file 2: Figure
S2, B, b1). In contrast, larger tumors showed more
heterogeneous expression with patches of cells show-
ing high ITSN-1s staining and other patches of cells
within the same tumor showing low ITSN-1s staining
Fig. 3 ITSN-1s impairs LC cell proliferation and growth. a A549 and A549 + ITSN cells (107) were seeded in 100 cm2 plates, cultured for five days,
trypsinized and counted. b Serial dilutions of A549 and A549 + ITSN-1s cells seeded in 96-well plates were subjected to the MTT assay. Cell proliferation
was assessed by absorbance at 570 nm; (w-well). c Three points on the linear part of the proliferation curve were used to evaluate the extent of cell
growth inhibition. Data are shown as percentage of control. d A549 and A549 + ITSN-1s cells (5×105) were seeded in 35 mm dishes in media with
0.28 % agar on a base of 0.58 % agar. Colonies began to form 30 days later, and were stained with crystal violet dye. Representative plates are shown.
e The number of colonies was quantified. Data are shown as percentage of control. Error bar represents mean ± SE; *p < 0.05; **p < 0.01. The above
data are representative of 3 independent experiments performed under identical experimental conditions. f A549 and A549 + ITSN cells (107) injected
into nude mice. Shown are representative tumors that formed 30 days post-injection. g Mean tumor area was measured using NIH ImageJ. Error bar
represents mean ± SE; (n = 3-5 mice); *p < 0.05
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(Additional file 2: Figure S2, D, d1). This supports the role
of ITSN-1s as a tumor suppressor.
ITSN-1s regulates cellular cytoskeleton organization
Since cancer cell migration and metastasis requires
reorganization of the cytoskeleton leading to epithelial-
mesenchymal transformation [38], we next addressed
whether decreased ITSN-1s protein level may be in-
volved in reorganization of the components of the cyto-
skeleton to favor migration and metastasis. Phalloidin
staining revealed small filaments of actin in A549 cells
(Fig. 5a), whereas in A549 + ITSN-1s cells it showed
thick bundles of actin pointing towards peripheral at-
tachment points (Fig. 5b, b1). In addition, A549 + ITSN-
1s compared to A549 cells showed more spreading and
loss of elongated and polarized morphology. Cell frac-
tionation and differential centrifugation of A549 and
A549 + ITSN-1s cell lysates followed by WB analyses
and densitometry showed no change in the G- and F-
actin fractions between the two cell lines (Fig. 5c),
suggesting that restoring ITSN-1s protein level does not
result in formation of new actin or actin polymerization,
Fig. 4 ITSN-1s impairs LC cell migration and metastasis. a A549 and A549 + ITSN-1s cell layer was wounded using a sterile micropipette tip and cells at
multiple points along the wound edge were imaged every 15 min over a 48 h period using time-lapse microscopy. Bar: 10 μm. b Measurements were
made using NIH ImageJ. Scratch closure was expressed as a percentage of initial scratch area in each well. c Scratch closure in mitomycin C treated
and untreated A549 and A549 + ITSN-1s cells were compared. Data are shown as percentage of control. Error bar represents the mean ± SE; **p < 0.01.
Data are representative of 3 independent experiments performed under identical experimental conditions. d Histological analyses of lung
metastasis in immunodeficient mice injected retroorbitally with A549 and A549 + ITSN-1s cells. Bar: 100 μm. e, f Total number as well as the
size of the lung metastasis per section was determined. Data are shown as median ± SE; **p < 0.01 (n = 5-7 mice). 5 lung sections per mice
were examined using identical parameters
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but simply reorganizes existing actin to form bundles.
Since association/dissociation of the actin cytoskeleton
structure with FA proteins determines cell motility and
metastasis [39], we performed double actin/vinculin im-
munofluorescent staining (Fig. 5d – i). A549 + ITSN-1s
cells had increased actin-vinculin colocalization (Fig. 5f,
f1) and a higher number of vinculin clusters per surface
area compared to A549 cells (Fig. 5j). The mean number
of vinculin clusters per 250 μm2 cell surface was 4.24 ±
0.8 vs. 10.4 ± 1.23 in A549 cells and A549 + ITSN-1s
cells respectively.
The other component of the cell cytoskeleton involved
in metastasis is vimentin intermediate filaments [40].
Immunofluorescence staining and image analyses showed
a wide spread vimentin filament network in A549
cells (Fig. 6a). A549 + ITSN-1s cells showed an altered
subcellular distribution of vimentin with collapse of
vimentin intermediate filaments into clusters of short fila-
ments near the nucleus (Fig. 6b). Next, WB using vimen-
tin Ab was applied on A549 and A549 + ITSN-1s cells
lysates as described under Methods. Full-length vimentin
filaments which are not soluble in lysis buffer are present
in the pellet, whereas the collapsed intermediate and small
filaments are soluble and present in the supernatant.
Densitometry analyses indicated decreased insoluble
vimentin and increased soluble vimentin in A549 + ITSN-
1s cells compared to A549 cells (Fig. 6c), consistent with
our morphological findings. Based on these findings and
previous reports indicating that the collapse of vimentin
filaments inhibits cancer progression [41], we concluded
that restoring ITSN-1s protein level stabilizes the cells
and contributes to decreased motility and metastasis.
Fig. 5 ITSN-1s increases actin bundles and number of FAs. Representative phalloidin staining of A549 (a) and A549 + ITSN-1s cells (b). Thick actin
filaments were often detected in A549 + ITSN-1s wells (B, boxed area, b1). Cell lysates were subjected to differential centrifugation to obtain the
G-actin and F-actin fractions, which were analyzed by WB with actin Ab followed by densitometry (c). Representative double fluorescent staining
with phalloidin (d, g) and vinculin/AF594 Ab (e, h) of A549 + ITSN-1s and A549 cells respectively. Co-localization of actin/vinculin is significant in
A549 + ITSN-1s (f, f1). Limited co-localization is detected in A549 (i). The number of vinculin clusters/250 μm2 cell surface was counted (j). Data
are representative of 3 independent experiments performed under identical experimental conditions. 50 cells per experiment were analyzed.
Images were acquired using identical parameters. Bars: 10 μm (A-I); 5 μm (b1, f1). Data are shown as mean ± SE; **p < 0.01
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ITSN-1s decreases mSos1-Eps8 interaction leading to
impaired activation of Rac1
Changes in cell cytoskeleton organization are mediated
by the GTPase proteins and it has been shown that
ITSN-1s interacts with mSos1, a GEF for Rac1, and with
CdGAP, a GAP for Cdc42 [6, 22, 23, 35]. We therefore
addressed whether ITSN-1s may regulate the activation
status of these proteins. A549 and A549 + ITSN-1s cell
lysates were subjected to Rac1, Cdc42 and RhoA activa-
tion assays (Fig. 7a). Densitometry demonstrated a 32 %
decrease in activated Rac1 and 18 % increase in RhoA
but no significant difference in activated Cdc42 in A549
+ ITSN-1s cells compared to A549 cells (Fig. 7b). These
findings are consistent with previous reports indicating a
reciprocal balance between Rac1 and RhoA [42, 43].
Rac1 is activated by interacting with mSos1-Eps8
complex which is formed in the presence of activation
of RTK [44]. Since ITSN-1s is an mSos1 interacting
protein, we performed IP of A549 and A549 + ITSN-
1s cell lysates with mSos1 Ab and WB with Rac1 Ab
to evaluate if restoring ITSN protein level interferes
with mSos1-Rac1 interaction. No detectable difference
was seen in the mSos1-Rac1 interaction between
A549 and A549 + ITSN-1s cells (Fig. 7c, upper panel).
The lower panels in Fig. 7c indicate the protein level
of Rac1 and mSos1 in A549 and A549 + ITSN-1s
lysates. As Eps8 is the other component of the com-
plex required for Rac1 activation, we next evaluated if
the level of ITSN protein level impacted mSos1-Eps8
interaction. IP using mSos1 Ab showed less mSos1-
Eps8 interaction in A549 + ITSN-1s cell lysates com-
pared to A549 cells (Fig. 7d, upper panel). Moreover,
WB of cell lysates revealed that the level of Eps8 pro-
tein is lower in A549 + ITSN-1s compared to A549
lysates, while the level of mSos1 protein is unchanged
(Fig. 7d, lower panels). Densitometry indicated that
restoring ITSN-1s decreased Eps8 protein level by
20 % and impaired the effective formation of mSos1-
Eps8 complex by 54 % (Fig. 7e).
ITSN-1s enhances Cbl-Eps8 interaction leading to
increased ubiquitination of Eps8
ITSN-1s is known to interact with Cbl and enhance its
activity leading to ubiquitination of important signaling
proteins [7, 8]. Therefore, we investigated if decreased
Eps8 protein level in A549 + ITSN-1s is due to its ubi-
quitination and degradation. Cells pretreated with
10 μM of MG132 (Sigma-Aldrich, St. Louis, MO) for
2 h and untreated cells were lysed and IP performed
with Eps8 Ab, followed by WB with both Eps8 (Fig. 8a,
lower panel) and ubiquitin (Fig. 8a, upper panel) Abs.
MG132 is a specific and potent proteasome inhibitor
which reduces the degradation of ubiquitin-conjugated
proteins [45]. Untreated A549 + ITSN-1s cells demon-
strated less full-length Eps8 compared to A549 cells and
additional bands above (Fig. 8a, arrows), which represent
the ubiquitinated Eps8 protein. The same protein bands
were immunoreactive to ubiquitin Ab (Fig. 8a, bracket).
Pretreatment with MG132 resulted in restoration of
Eps8 protein level (Fig. 8a, lower panel) and marked
Fig. 6 ITSN-1s collapses vimentin filaments. Immunofluorescence staining using vimentin/AF594 Ab demonstrate a widespread vimentin filament
network in A549 cells (a) and an altered subcellular distribution of vimentin with collapse of vimentin intermediate filaments into clusters of short
filaments near the nucleus in A549 + ITSN-1s cells (b). Biochemical analysis and densitometry of full length and collapsed vimentin filaments in
A549 and A549 + ITSN-1s cells lysates (c). Data are representative of 3 independent experiments performed under identical experimental
conditions. 50 cells per experiment were analyzed. Images were acquired using identical parameters. Bars: 10 μm (a, b). Data are shown as
mean ± SE, *p < 0.05
Jeganathan et al. Molecular Cancer  (2016) 15:59 Page 11 of 17
Fig. 7 ITSN-1s impairs mSos1-Eps8 leading to deactivation of Rac1. a Representative PAK/Rhotekin-GST pull-down assays applied on A549 and
A549 + ITSN-1s cell lysates followed by WB with Rac1, Cdc42 and RhoA Abs. b Data are shown as percentage of control. Total Rac1, Cdc42, RhoA
and GTP/GDP loaded lysates were uses as control. c, d A549 and A549 + ITSN-1s cell lysates were subjected to IP with mSos1 Ab, followed by WB
with Rac1 (c, upper panel) and Eps8 (d, upper panel) Abs. The lower panels in c and d illustrate the Rac1, mSos1 and Eps8 protein levels in A549
and A549 + ITSN-1s cell lysates. Mouse IgG was used as control (not shown). e Densitometry of Eps8-mSos1 interaction expressed as percentage
of control. All data are representative of 3 independent experiments performed under identical experimental conditions
Fig. 8 ITSN-1s enhances Cbl-Eps8 interaction leading increased ubiquitination of Eps8. a A549 and A549 + ITSN-1s cells pretreated with MG132
(10 μM for 2 h) and untreated cells were lysed and subjected to IP with Eps8 Ab followed by WB with Eps8 and Ub Abs. Arrows and bracket show
ubiquitinated Eps8. b Densitometry of Ub-Eps8 expressed as percentage of control. c IP with Cbl Ab followed by WB with Eps8 Ab. The lower panels
illustrate the Cbl and Eps8 protein levels in A549 and A549 + ITSN-1s cell lysates. Rabbit IgG was used as control (not shown). d Densitometry of Eps8-
Cbl interaction expressed as percentage of control. e A549 and A549 + ITSN-1s cells transfected with Cbl-siRNA#1 and #2 or control-siRNA. Lysates were
blotted with Cbl Ab (middle panel) followed by Eps8 Ab (upper panel). Actin was used as loading control (lower panel). Data are shown as mean ± SE.
*p < 0.05; All data are representative of 3 independent experiments performed under identical experimental conditions
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accumulation of ubiquitinated Eps8 (Fig. 8a, upper
panel), indicating that ITSN-1s mediated downregula-
tion of Eps8 is via proteasomal degradation. In the pres-
ence of MG132, A549 + ITSN-1s cells showed relatively
limited accumulation of ubiquitinated Eps8 when com-
pared to A549 cells (Fig. 8b). To confirm that Eps8 ubi-
quitination is via Cbl, we performed IP with Cbl Ab and
WB with Eps8 Ab (Fig. 8c) which demonstrated in-
creased interaction between Cbl and Eps8 in A549+
ITSN-1s cells (Fig. 8c, upper panel). The lower panels in
Fig. 8c indicate the level of Cbl and Eps8 in the A549
and A549 + ITSN-1s lysates. Densitometry analyses in-
dicate that ITSN restoration improved the effective for-
mation of Cbl-Eps8 complex by 83 % (Fig. 8d). To
further validate that Eps8 degradation is via Cbl, we
used a siRNA approach to knockdown Cbl protein level.
A549 and A549 + ITSN-1s cells were transfected with
Cbl-siRNA and control-siRNA (Fig. 8e). Cbl protein
level was unaffected by control-siRNA, whereas Cbl-
siRNA efficiently knocked down the Cbl protein level in
A549 and A549 + ITSN-1s cells (Fig. 8e, middle panel).
Moreover, transfection with control-siRNA showed deg-
radation of Eps8 in A549 + ITSN-1s cells (Fig. 8e, upper
panel-left 2 lanes). However, with Cbl knockdown, Eps8
degradation in A549 + ITSN-1s cells was prevented
(Fig. 8e, upper panel-right 4 lanes).
In summary, our studies show that restoring ITSN-
1s increases Cbl-Eps8 interaction leading to Eps8 ubi-
quitination and degradation. The preferential forma-
tion of Cbl-Eps8 contributes to impaired assembly of
Eps8-mSos1 complex, leading to Rac1 inactivation,
reorganization of actin into thick bundles, increased
FA complexes and collapse of the vimentin filament
network altogether leading to decreased LC cell migra-
tion and metastasis (Fig. 9).
Discussion
Our study is the first to investigate the role of ITSN-1s
in LC. We found that ITSN-1s level is consistently low
in all LC tissues and LC cell lines. Based on our pilot
data demonstrating a negative correlation between
ITSN-1s level and the aggressiveness of LC, further
studies will be performed to evaluate the use of ITSN-1s
as a biomarker to predict the aggressiveness and progno-
sis of LC. The goal of this study was to evaluate the
mechanisms involved, and the impact of ITSN-1s defi-
ciency in LC progression. Our studies demonstrate that
ITSN-1s deficiency plays a significant role in all the key
stages of LC – cell proliferation, anchorage-independent
growth, migration and metastasis. These findings are con-
sistent with our previous studies using animal models of
human disease and human tissue which demonstrated
that chronic ITSN-1s deficiency of lung tissue triggers
phenotypic changes toward proliferation [9, 16, 17]. Our
findings are also consistent with the clinical evidence
demonstrating a lower incidence of LC in patients with
Down syndrome who overexpress ITSN-1s protein [25].
The Human Protein Atlas reports significantly lower
levels of ITSN-1s level in LC and a number of other solid
organ malignancies which further supports our data [46].
However, contrary to our findings, studies in neuroblast-
oma and glioblastoma have shown upregulation of ITSN-
1s and reduced tumorigenesis and cell migration with
silencing of ITSN-1s [47–49]. This demonstrates that
ITSN-1s medicated interactions and regulation of signal-
ing pathways are specific to the tissue and disease. There
are a number of minor splice variants of ITSN-1s protein
which facilitate tissue specific interactions. This is illus-
trated in the fact that ITSN-1s preferentially interacts with
mSos1 and Cbl in most tissues including lung, however, in
brain tissue a splicing of microexon 20 within the SH3A
Fig. 9 Proposed mechanism for ITSN-1s-mediated Eps8/Cbl/Sos1 interaction and Rac1-dependent LC cell migration and metastasis. ITSN-1s enhances
Cbl-Eps8 interaction leading to ubiquitination and degradation of Eps8. The preferential formation of Cbl-Eps8 leads to impaired assembly of Sos1-
Eps8, leading to deactivation of Rac1. Rac1 deactivation reorganizes the cytoskeleton structure to increase thick actin bundles, increase focal adhesion
complexes and collapse of the vimentin filament network altogether leading to decreased LC cell migration and metastasis
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domain of ITSN-1s (resulting in inclusion of 5 additional
amino acids) leads to reduced binding to mSos1 and Cbl
and enhanced interaction with CdGAP [50].
ITSN-1s’ interaction with CdGAP and mSos1 has been
shown to regulate the activity of GTPase proteins. How-
ever, ITSN-1s does not have a GEF domain like ITSN-1l
(C-terminal DH-PHdomains act as a GEF). ITSN-1s’
interaction with CdGAP inhibits its GAP activity leading
to activation of Cdc42 and Rac1 [22]. ITSN-1s’ inter-
action with mSos1 is more complex. The SH3 domains
of ITSN-1s form a stable complex with mSos1 and com-
pete with Grb2 for binding to the same site on mSos1.
Consistent with this, overexpression of the SH3 domains
of ITSN impairs mSos1-Grb2 complex and prevents
Ras-mediated MAPK activation [6, 35]. However, over-
expression of full length ITSN-1s was shown to activate
Ras in the perinuclear vesicles without downstream acti-
vation of the MAPK pathway [51]. ITSN-1s mediated
Ras activation in the perinuclear vesicles was initially
thought to be via mSos1 but recent studies have dis-
proved this and have implicated a novel PI3K isoform in
this interaction [49]. Given the wide subcellular distribu-
tion of ITSN-1s, it is not surprising that ITSN-1s has
unique interactions and regulates different signaling
pathways depending on the intracellular compartment
and its spatial orientation.
The role of ITSN-1s in the regulation of cell migration
and the underlying mechanism has not been previously
reported. It is well-known that Eps8 interacts with
mSos1 in the presence of RTK activation to convert the
Rac1 GTPase from its inactive GDP-bound state to the
active GTP-bound state [20]. The role of ITSN-1s in
mSos1 GEF activity towards Rac1 has not been previ-
ously reported. Our studies demonstrate that full length
ITSN-1s impairs mSos1-Eps8 interaction and favors
Cbl-Eps8 interaction leading to impaired Rac1 activation
and Eps8 ubiquitination respectively. E3 ubiquitin li-
gases, especially Cbl, play an important role in regulating
the level of numerous proteins [52]. Mutations and de-
regulation of Cbl are highly prevalent in LC [19]. Herein,
for the first time, we have shown that Eps8 protein level
is regulated by Cbl and have demonstrated that ITSN-1s
is an important mediator of this interaction. We pre-
dicted the interaction is most likely between the SH3 do-
main(s) of ITSN and the proline-rich regions of Eps8
and Cbl, similar to ITSN’s interactions with most signal-
ing proteins [53]. Our additional studies (unpublished)
indeed demonstrate direct interaction between ITSN-1s’
SH3 domains and Eps8. Our work in progress aims to
identify the specific SH3 domain(s) of ITSN-1s involved,
and map the specific region of the domain involved in
the interaction. Prior study by Ding et al. reported direct
interaction between ITSN-2 and Eps8 but via the CC re-
gion [54]. Although the CC region is one of the less
conserved regions between ITSN-1 and ITSN-2 [15], in
future studies we will explore if there is a role for the
ITSN-1s’ CC region in the regulation of Eps8. The mul-
tiple domains of ITSN-1s are known to simultaneously
interact with the same protein as well as different pro-
teins [55]. Given the presence of 5 SH3 domains, it is
likely that ITSN-1s is able to simultaneously interact
with multiple proline-rich domains of proteins to coord-
inate different cellular signaling processes. ITSN defi-
ciency leading to impaired Cbl-Eps8 interaction, and
enhanced mSos1-Eps8 complex formation leading to Rac1
activation, is a mechanism which has not been previously
reported in cancer. ITSN’s impact on EGFR protein level
and potential impact on mSos1-Eps8 interaction and Eps8
ubiquitination cannot be ruled out.
Recognizing ITSN-1s deficiency as a key player in Rac1
activation is significant since Rac1 is the most important
regulator of the cytoskeleton structure with control over
epithelial-mesenchymal transition, cell migration and me-
tastasis of LC [56]. The other GTPases, Cdc42 and Rho,
are not able to drive cell migration efficiently in the ab-
sence of Rac1 [57]. Rac1 has a complex reciprocal rela-
tionship with RhoA, and the balance between the two
determines cell migration by reorganizing cytoskeleton el-
ements and focal adhesions [43, 58]. Consistent with this,
our studies showed decreased Rac1 activation, increased
RhoA activation and significant cytoskeleton modification
with ITSN-1s restoration. Compared to A549 cells, A549
+ ITSN-1s cells showed increased spreading, lack of elon-
gated and polarized morphology and prominent actin
bundles towards peripheral attachment points. These find-
ings are consistent with previous observations in Rac1 de-
ficient cells [57] and are likely due to a change from a
mesenchymal to amoeboid type of cell migration seen
with decreased Rac1 and activation of RhoA [58]. In
addition, we noted an increase in the number of vinculin
focal adhesions at the cell surface of A549 + ITSN-1s cells.
Vinculin deficient cells have impairment of traction,
spreading and ECM adhesion all leading to increased
cell motility [39]. Activated vinculin binds to integrin and
cadherin and mediates cell-ECM and cell-cell junctions
to stabilize cells. Upregulation of vinculin increases
E-cadherin (epithelial marker) and downregulation increases
vimentin (mesenchymal marker) [59]. Consistent with
this concept, the wide subcellular distribution of vimen-
tin filaments present in A549 cells was collapsed in the
perinuclear area in A549 + ITSN-1s cells. The impaired
formation of vimentin filaments in A549 + ITSN-1s cells
could also be due to impaired PAK activation as a result
of decreased Rac1 activation [60]. Besides Rac1, there
may be other proteins and signaling pathways involved
in cytoskeleton regulation, possibly impacted by regula-
tion of ITSN-1s level, but not explored in this study. As
an actin-capping protein, it is possible that in addition
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to its effects via Rac1, Eps8 may also have directly con-
tributed to changes to the actin cytoskeleton [21].
Our findings of decrease in cell proliferation, in
anchorage-independent growth and in tumor growth with
restoration of ITSN-1s protein level is contrary to previ-
ous studies showing increased Ras activation which is
known to drive cell proliferation and tumorigenesis [61].
However, studies have shown that Rac1 activation is a
pre-requisite for Ras-mediated tumor progression [62].
Rac1 activation could also directly activate JNK pathway
leading to tumor progression [63]. As an oncoprotein,
Eps8 also translocates to the nucleus and upregulates nu-
merous cell cycle proteins such as transcription factor
FOXM1 [64]. Therefore, ITSN-1s mediated inhibition of
tumorigenesis is likely due to a combined inhibitory effect
on these pathways. In addition, ITSN-1s enhances ubiqui-
tination and downregulation of EGFR with a potential
negative impact on proliferation [7].
Conclusion
We demonstrate that restoring ITSN-1s protein level
impairs both proliferation and anchorage-independent
growth, and restores cytoskeleton changes in favor of
decreased cell migration and metastasis. Based on these
results, we propose a novel mechanism of LC regulation
triggered by ITSN-1s deficiency, consistent with the idea
that low ITSN-1s decreases Eps8-Cbl interaction and
enhances the assembly of Eps8-mSos1 complex, leading
to upregulation of Eps8 and activation of Rac1. ITSN-1s’
ability to reverse the malignant features demonstrates
the capability of this protein to regulate multiple path-
ways simultaneously which makes it an attractive thera-
peutic target. Further validation of ITSN-1s protein level
in a large cohort of patients at different stages of LC
could establish ITSN-1s as a predictor of prognosis and
indicator of response to therapy. Given the ubiquitous
distribution of ITSN-1s and evidence that loss of ITSN-
1s is a characteristic feature of many cancers [46], our
findings may be applicable to other types of cancer.
Additional files
Additional file 1: Figure S1. ITSN-1s impairs LC cell migration. (A) A549
and A549 + ITSN-1s cells were grown to confluence in 3 sets in triplicate -
1 set of cells were trypsinized and counted (controls), 1 set was
subjected to treatment with mitomycin C (7.5 μg/ml for 1 h) and the
other set was untreated. We studied in preliminary experiments, different
concentrations and duration of treatment (ranging from 5 μg/ml to 20 μg/ml
and 45 min to 4 h) and determined that 7.5 μg/ml of mitomycin C treatment
for 1 h provided the ideal results (>90 % inhibition of proliferation without
killing the cells). The latter 2 sets were cultured for an additional 24 h. After
24 h all cells were trypsinized and counted. The following formula was used
to calculate cell proliferation for mitomycin C treated and untreated cells:
(Average cell count of set – Average cell count of control)/Average cell count
of control × 100 %. The results are reported as percentage of A549 untreated
cells. Error bar represents the mean ± SE; **p< 0.01. Data are representative of
3 independent experiments performed under identical experimental
conditions. (B) A549 and A549 + ITSN-1s cells were grown to confluence in
2 sets in triplicate, 1 set was subjected to treatment with mitomycin
C (7.5 μg/ml for 1 h) and the other set was untreated. Mitomycin C treated
and untreated A549 and A549 + ITSN-1s cell layer was wounded using a
sterile micropipette tip; the area was examined after 24 h with phase
contrast microscopy. Data are representative of 3 independent experiments
performed under identical experimental conditions. (TIF 2992 kb)
Additional file 2: Figure S2. ITSN-1s expression in emerging tumors.
Immunofluorescent staining with ITSN-1 Ab followed by AF488 Ab of
lung sections from mice injected retro-orbitally with A549 (A, C) and
A549 + ITSN-1s (B, D) cells. Representative images of small tumors (A, B,
b1) and medium/large tumors (C, D, d1) in mice injected with A549 and
A549 + ITSN-1s cells respectively. 3 sections per mice (n = 3 mice) were
examined and images were acquired using identical parameters. Bars:
40 μm. (TIF 3224 kb)
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